Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Purchases $79,600.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director John B. Bode bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at $318,400. The trade was a 33.33 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $8.01 on Monday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The business has a 50 day moving average price of $7.90 and a two-hundred day moving average price of $8.19. The stock has a market cap of $433.47 million, a PE ratio of -4.07 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million. As a group, sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Several large investors have recently modified their holdings of the business. Woodline Partners LP lifted its stake in shares of Zevra Therapeutics by 2.2% in the fourth quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock worth $34,524,000 after acquiring an additional 90,940 shares in the last quarter. Velan Capital Investment Management LP increased its holdings in Zevra Therapeutics by 50.0% during the 4th quarter. Velan Capital Investment Management LP now owns 300,000 shares of the company’s stock worth $2,502,000 after purchasing an additional 100,000 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after purchasing an additional 4,384 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Zevra Therapeutics in the 4th quarter valued at approximately $145,000. Finally, Millennium Management LLC boosted its stake in shares of Zevra Therapeutics by 138.2% during the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company’s stock valued at $1,944,000 after buying an additional 135,246 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on ZVRA shares. Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Canaccord Genuity Group increased their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday, March 13th. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $22.29.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.